Market Research Industry Reports

Therapeutic Class Report Overview - Japan Biosimilars

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
200b worth of biologic products is going off patent by 2015 and this value exceeds ~ 500b if we include products that will see their patent expiries by 2021 in Japan. There are a number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story of generic preliminary because the much higher cost of biologic therapy brings significant burden on patients despite relatively low co-pay in Japan and this will push individuals and DPC Hospitals to use biogeneric products to a greater extent unlike generic drugs. Secondly, the regulatory supports are going to be stringent enough to ensure quality measures and leave ~no room for imported products, thus eliminating the not made in Japan factor from prescribers and users mindsets.

Anticipating this opportunity and favorable macro forces as compared to generics, a number of companies aim to exploit this Japan has seen a flood like consolidation and partnering activities in biosimilar space. While a dozen+ companies have already laid their road map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan.

In this piece, we attempt to evaluate the future competitive landscape of the biosimilars space in Japan, assess the overall attractiveness of the same, and try to identify the key determinates to succeed in this space.
N/A

List Of Tables

N/A

List Of Figures

N/A

Frequency Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Frequency Therapeutics Inc (Frequency Therapeutics) is a biotechnology company which develops progenitor cell activation (PCA) therapies. The companys small molecule drugs are used to activate progenitor cells for restoration of

USD 250View Report

Feldan Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Feldan Therapeutics Inc (Feldan), formerly Feldan Bio Inc, is a biotechnology company with focus on the discovery, development, manufacture and marketing of recombinant proteins. The company developed a peptide-based technology

USD 250View Report

Therapeutic Class Report Overview - Future Of GPR Agonist

Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening

USD 1000View Report

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations

USD 1000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1000
  • Site Licence    USD 2000
  • Enterprisewide Licence    USD 3000
$ 1000

Reports Details

Published Date : Jan 2013
No. of Pages :32
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube